Amicus Therapeutics (FOLD) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amicus Therapeutics Announces Third Quarter 2017 Financial Results and Corporate Updates
November 8, 2017 7:00 AM EST260+ Fabry Patients on Reimbursed Galafold (Migalastat) and On Target to Reach 300 Patients by Year-End 2017
U.S. NDA Submission for Migalastat Planned in 4Q17
Pompe Retrospective and Prospective Data Collection Studies Initiated
Additional Pompe Clinical Data to be Presented at WORLDSymposium in February 2018
CRANBURY, N.J., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company at the forefront of... More
